SEC 13F Intelligence

Managers / Q1 2026

Lunate Capital Ltd

CIK 0002056786 · UNIT 1, FLOOR 12, AL MARYAH TOWER, ABU DHABI GLOBAL MARKET SQUARE, AL MARYAH ISLAND, ABU DHABI, C0, 00000 · 971.2.877.8896

Reported Value
$120M
Q1 2026
Positions
6
Filings on Record
6
2019–present window
Filed
Apr 16, 2026
original filing

Summary

Lunate Capital Ltd reported $120M in U.S.-listed holdings across 6 positions for Q1 2026.

The portfolio is heavily concentrated: RVMD alone accounts for 44.4% of reported value.

The book was largely unchanged from Q4 2025.

Portfolio Metrics

Turnover
+0.4%
vs prior filed quarter
Largest Position
+44.4%
Revolution Medicines

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’25: $171MQ1 ’25Q2 ’25: $178MQ2 ’25Q3 ’25: $221MQ3 ’25Q4 ’25: $264MQ4 ’25Q1 ’26: $120MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 83.0%REIT: 16.3%Equity WRT: 0.7%
  • Common Stock · 83.0% · $100M
  • REIT · 16.3% · $20M
  • Equity WRT · 0.7% · $805,500

Quarter-over-Quarter Changes full breakdown →

vs Q4 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
RVMDREVOLUTION MEDICINES INCTRIMMED1.65M549.0K$122M$53M
SAILSAILPOINT INCHELD+03.00M$21M$40M
LINELINEAGE INCHELD+0600.0K$1M$20M
NAVNNAVAN INCHELD+0200.0K$768,000$3M
RVMDWREVOLUTION MEDICINES INCHELD+0450.0K+$382,545$805,500
NMRANEUMORA THERAPEUTICS INC.HELD+02.12M+$339,863$4M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2026

5 positions
#IssuerClass% PortfolioValueShares
1RVMDREVOLUTION MEDICINES INCCOM · *W EXP 12/17/20245.03%$54M999.0K
2SAILSAILPOINT INChistory →COM33.00%$40M3.00M
3LINELINEAGE INChistory →COM16.33%$20M600.0K
4NMRANEUMORA THERAPEUTICS INC.history →COM3.44%$4M2.12M
5NAVNNAVAN INChistory →CL A2.20%$3M200.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$120M6Apr 16, 202613F-HRchanges · EDGAR ↗
Q4 2025$264M6Jan 23, 202613F-HRchanges · EDGAR ↗
Q3 2025$221M6Nov 20, 2025RESTATEMENTchanges · EDGAR ↗
Q2 2025$178M6Jul 17, 202513F-HRchanges · EDGAR ↗
Q1 2025$171M4Apr 25, 202513F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 1 additional manager.

  • Lunate Holding RSC Ltd028-25201

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.